Gongwin Biopharm Holdings (6617) Fundamentals 2026 — Revenue Analysis | SniperIQ
Gongwin Biopharm Holdings (6617) is a TW-listed Healthcare company in Medical - Distribution with a market capitalization of NT
6M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gongwin Biopharm Holdings's market cap?
Gongwin Biopharm Holdings (6617) has a market capitalization of approximately NT
What is Gongwin Biopharm Holdings's P/E ratio?
Gongwin Biopharm Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gongwin Biopharm Holdings?
Gongwin Biopharm Holdings runs a net profit margin of -371.0%, a gross margin of 35.0%, and an operating margin of -588.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gongwin Biopharm Holdings generate?
Gongwin Biopharm Holdings reported revenue of NT
Does Gongwin Biopharm Holdings pay a dividend?
Gongwin Biopharm Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Gongwin Biopharm Holdings financially healthy?
Gongwin Biopharm Holdings carries a debt-to-equity ratio of 0.06x and a current ratio of 9.19x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gongwin Biopharm Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gongwin Biopharm Holdings (6617) the key facts are: market cap NT
6M, 52-week range 58.3-120. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.Track Gongwin Biopharm Holdings's full fundamentals live
Get Gongwin Biopharm Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.